nivolumab + fluorouracil + cisplatin

Nivolumab + fluorouracil + cisplatin is a three-drug combination regimen consisting of: - **Nivolumab**, a monoclonal antibody immune checkpoint inhibitor that targets programmed death-1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance T-cell antitumor immune responses - **Fluorouracil**, a pyrimidine antimetabolite chemotherapy that inhibits thymidylate synthase, interfering with DNA synthesis - **Cisplatin**, a platinum-based chemotherapy that crosslinks DNA, inducing apoptosis This combination is primarily developed and approved as first-line treatment for adults with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), and particularly those with tumor cell programmed death ligand 1 (PD-L1) expression ≥1%[1][2][4][5]. The regimen was studied in the phase III CheckMate 648 trial, showing improved overall survival compared to chemotherapy alone in this population. The combination leverages the immunotherapeutic benefit of checkpoint inhibition with the cytotoxic effects of platinum and fluoropyrimidine chemotherapy[1][2][5].

Other names

nivolumabcisplatin5-fluorouracil5-FU